Navigation Links
NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs
Date:6/17/2010

Rome, Italy, Thursday 17 June 2010: The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought to be a regulator of cardiovascular function) as a robust, non-invasive predictor of cardiovascular (CV) risk in patients with arthritis taking cyclooxygenase inhibitors has been reinforced by the results of a multinational study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

The presence of NT-proBNP was associated with a range of CV outcomes, including CV death (p= < 0.0001), myocardial infarction (MI) (p=0.02), heart failure (HF) (p=0.004) and a composite of thrombotic events (CV death, MI, or stroke) (p= < 0.0001). This marker for CV risk remained strongly predictive of CV events after adjustment for age, sex, diabetes, hypertension, type of arthritis, body mass index (BMI), renal function and history of prior CV disease. The results of this multinational trial, which involved The Thrombolysis in Myocardial Infarction (TIMI) Study Group, evaluated 2-year CV outcomes in 6,273 patients with rheumatoid arthritis (RA) and osteoarthritis treated with the non-steroidal anti-inflammatory treatments etoricoxib or diclofenac.

"This study has validated previous research showing that NT-proBNP is a strong indicator for cardiovascular risk in arthritis patients," said Professor Kay Brune, lead author, Department of Pharmacology, University of Erlangen, Erlangen, Germany. "This means that clinically, the presence of NT-proBNP can be used to accurately assess a patients' CV risk, meaning that appropriate treatment options can be identified early on."

Furthermore, the assessment of CV disease risk in patients with Rheumatoid Arthritis (RA) was studied in a separate 15-year follow-up study of Norwegian patients. The study aimed to determine whether early markers of RA inflammatory disease activity could predict arterial stiffness, a surrogate marker of CV disease. Arterial stiffness was measured as Pulse Wave Velocity (PWV) and Augmentation Index (AIx).

"From this research, we can now say that certain inflammatory markers seem to be independent, longitudinal predictors of CV risk in RA patients. Treatment options that help manage early inflammation in patients with RA may ensure that the long-term CV risk associated with RA is managed appropriately," said Dr. Sella Provan, Diakonhjemmet Hospital, Oslo, Norway, and lead author of the study.

In the Norwegian study, patients with elevated baseline C-reactive protein (CRP, a blood protein, levels of which may rise in response to certain types of inflammation) had a significantly higher AIx Beta co-efficient Confidence Interval (β(CI) 2.67 (0.06-5.31) p=0.045) and PWV after 15 years (β(CI) 0.08 (0.01-0.14) p=0.02) after adjustments for age, sex and mean arterial pressure (MAP). Baseline elevated CRP remained a significant predictor of increased AIx after adjustment for possible current confounders.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. UBC-Providence health team identifies a key predictor of cardiovascular death
2. Family history is strong predictor of obstructive coronary artery disease using CCTA
3. Plaque on CT scan is strong predictor of heart disease, worse long-term outcomes
4. Researchers receive NIH grant to study predictors and outcomes of autoimmune lung disease
5. Ultrasound measurement of fetal adrenal gland a better predictor of preterm birth
6. Almost three quarters of women with rheumatoid arthritis worldwide suffer pain daily
7. Osteoarthritis Claims Growing Number of Younger Victims
8. Out-of-Pocket Costs Limit Access to Arthritis Drugs
9. Massage Envy Provides Effective Way to Manage Arthritis Pain
10. O2 Media's Hit Morning Show &#8216;The Balancing Act' Welcomes the Arthritis Foundation to the Program
11. Jeffrey Gottfurcht Children's Arthritis Foundation Launches With Mount Everest Climb
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's ... goals for each and every seminar, session and class she offers. At ... brainwave tools which help energize creativity, focus mental functions, enhance athletic focus and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
(Date:2/16/2017)... 16, 2017 Research and Markets has announced ... Analysis & Trends - Function, Application, Cancer Type, Technology - Forecast ... ... Market is poised to grow at a CAGR of around 28.6% ... Some of the prominent trends that the ...
Breaking Medicine Technology: